Headache treatment methods are described and include providing, an energy delivery device; locating a secondary or higher-order branch of a postganglionic nerve that provides innervation for a patient's head, by identifying a target region of the patient's head that includes the nerve branch; positioning, within the target region, a portion of the energy delivery device; and applying, from the positioned portion of the energy delivery device to the target region, an amount of energy effective to result in a stimulation activity of the nerve branch; and, after observing the stimulated nerve branch activity, delivering, from the energy delivery device to the nerve branch, energy in an amount effective to reduce a headache severity in the patient.

An improved external trial stimulator provides neurostimulation functionality for implanted medical electrodes prior to implantation of an implantable neurostimulator. The external trial stimulator is housed in a four-part housing that provides mechanical and electrostatic discharge protection for the electronics mounted in a central frame of the housing. Connectors attached to leads from the electrodes connect to contacts that are recessed in the housing through ports that are centered for easy access. Multiple indicators provide information to users of the external trial stimulator.

Catheter-based devices and associated methods for immune system neuromodulation of human patients are disclosed herein. One aspect of the present technology is directed to methods of treating a human patient diagnosed with an immune system condition. The methods can include intravascularly positioning a neuromodulation catheter within a blood vessel proximate to neural fibers innervating an immune system organ of the patient. The method also includes reducing sympathetic neural activity in the patient by delivering energy to the neural fibers innervating the immune system organ via the neuromodulation catheter. Reducing sympathetic neural activity improves a measurable physiological parameter corresponding to the immune system condition of the patient.

A skin treatment device is provided, which includes a needle frame in which a front end outlet of a needle that penetrates an inside thereof projects toward a front thereof, a rear end inlet of the needle is open to an outside of a rear surface thereof, and a stepped partition wall is provided in a closed shape on the outside of the rear surface thereof; a needle cover having a space portion formed on a rear thereof toward an inside thereof, a needle guide portion formed on a front surface thereof; a contact PCB configured to receive a power that is supplied from a power supply device; and a needle hub having an insertion portion formed in a front thereof toward an inside thereof.

A control system for a movement reconstruction and/or restoration system for a patient, comprising at least one sensor, at least one controller, at least one programmer, at least one stimulation system,
wherein the controller is connected with the sensor, the programmer and the stimulation system,
wherein the sensor is part of or attached to a training entity in order to create and/or guide a movement model for a patient and/or adjust stimulation settings based on sensor input.

An introducing device for locating a tissue region and deploying an electrode is shown and described. The introducing device may include an outer sheath. An inner sheath may be disposed within the outer sheath. The inner sheath may be configured to engage an implantable electrode. In an example, the inner sheath may comprise a stimulation probe having an uninsulated portion at or near a distal end of the delivery sheath. The outer sheath may be coupled to a power source or stimulation signal generating circuitry at a proximal end. A clinician may control application of the stimulation signal to a tissue region via the outer sheath.

Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Neurostimulation assemblies, systems, and methods make possible the providing of short-term therapy or diagnostic testing by providing electrical connections between muscles and/or nerves inside the body and stimulus generators and/or recording instruments mounted on the surface of the skin or carried outside the body. The assembly affords maximum patient mobility and comfort through differentiated components having minimal profiles and connected by way of detachable and adjustable connections.

A wearable, percutaneous device for suppressing appetite or hunger in a patient includes a microprocessor, electrical stimulator and at least one percutaneous electrode implanted and configured to deliver electrical stimulation through the patient's skin. The percutaneous device includes a pad and at least one needle, in which the electrode is disposed, for secure placement of the device within the skin of a patient. The percutaneous device is adapted to provide electrical stimulation as per stimulation protocols and to communicate wirelessly with a companion control device configured to monitor and record appetite patterns of the patient. The control device is also configured to monitor, record, and modify stimulation parameters of the stimulation protocols.

An introducing device for locating a tissue region and deploying an electrode is shown and described. The introducing device may include an outer sheath. An inner sheath may be disposed within the outer sheath. The inner sheath may be configured to engage an implantable electrode. In an example, the inner sheath may comprise a stimulation probe having an uninsulated portion at or near a distal end of the delivery sheath. The outer sheath may be coupled to a power source or stimulation signal generating circuitry at a proximal end. A clinician may control application of the stimulation signal to a tissue region via the outer sheath.